オプションチェーンは、FOXO Technologiesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、FOXO Technologiesの市場センチメントを評価します。.

FOXO Technologies (AMEX:FOXO) 株価情報, オプションチェーン

FOXO Technologies

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. The company's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life. The Company manages and classifies its business into two reportable business segments: Healthcare; and Labs and Life.

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are in the spotlight Tuesday after rallying 26% to start the week. Here&#8217;s a look at <a href="https://www.benzinga.com/news/earnings/25/04/45038400/plug-power-rallies-as-new-financing-cost-cuts-boost-confidence-in-turnaround-plan">what&#8217;s going on</a>.
What Happened: Plug Power shares raced higher on Monday after the company reported preliminary first-quarter results and announced it secured a credit facility of up to $525 million.
Plug said it signed a definitive agreement with Yorkville Advisors for a secured debt facility that includes the issuance of up to&nbsp;$525 million&nbsp;of secured debentures. The arrangement includes an initial&nbsp;$210 million&nbsp;tranche, which will be fully funded at the initial closing, along with additional tranches of up to&nbsp;$315 million.&nbsp;
Plug Power said it expects to report first-quarter revenue of approximately $130 million to $134 million. Analysts are anticipating first-quarter earnings of $131 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. 
The company noted that it expects net cash usage in the first quarter of approximately $142 million, compared to $268 million in the first quarter of 2024. 
&#8220;Plug anticipates additional near-term reductions to net cash usage driven by hydrogen plant ramp-ups, additional cost downs, and additional price increases,&#8221; the company said. 
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a>
Plug reported that it had $296 million in unrestricted cash as of March 31. The company is due to report audited first-quarter results in early May. In the preliminary release, the company also provided guidance for the second quarter.
Plug expects second-quarter revenue to be in the range of $140 million to $180 million versus estimates of $143.35 million. 
&#8220;We&#8217;ve made the tough decisions and put the structure in place to deliver improved operating leverage and capital efficiency,&#8221; said Andy Marsh, CEO of Plug Power. 
&#8220;Between strengthening our balance sheet, scaling hydrogen production, and streamlining operations, we&#8217;ve taken the right steps to position Plug for long-term success in the hydrogen economy.&#8221;
PLUG Price Action: <a href="http://benzinga.com/quote/PLUG">Plug shares</a> raced higher on Monday following the announcements. The stock was pulling back Tuesday at last check, down 4.5% at 97 cents at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: T. Schneider/Shutterstock.

Earnings

News

Guidance

Movers

PLUG

Plug Power Stock Is Trending Tuesday: What's Going On?

Scotiabank analyst Divya Goyal maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Sector Perform and lowers the price target from $170 to $140.

Price Target

Analyst Ratings

GLOB

Scotiabank Maintains Sector Perform on Globant, Lowers Price Target to $140

Scotiabank analyst Divya Goyal maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Sector Outperform and lowers the price target from C$185 to C$175.

TSX:GIB

TSX:GIB/A

Scotiabank Maintains Sector Outperform on CGI, Lowers Price Target to C$175

On Tuesday, Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported first-quarter 2025 adjusted EPS of 92 cents, compared to 82 cents a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of 67 cents</a>.
Pfizer&#8217;s sales fell 8% year over year to $13.71 billion, slightly below the consensus of $13.95 billion. This reflects an operational decrease of $908 million, or 6%, as well as an unfavorable impact of foreign exchange of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45061905/pfizer-reports-solid-first-quarter-2025-results-and-reaffirms-2025-guidance" rel="noreferrer noopener">$256 million, or 2%</a>.
The operational decrease was primarily driven by a decline in Paxlovid revenues, partially offset by growth from the Vyndaqel family, Comirnaty, and several other products across categories despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" rel="noreferrer noopener">Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient</a>
Quarterly Comirnaty&nbsp;revenues of $565 million increased 62% operationally compared with the prior-year quarter. Paxlovid revenue fell 75% operationally to $491 million.
Vyndaqel family drugs generated&nbsp;<a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2025/q1/Q1-2025-PFE-Earnings-Release-FINAL.pdf" rel="noreferrer noopener">sales</a> of $1.49 billion, up 33%. Eliquis, a blood thinner drug, generated sales of $1.92 billion, down 4%.
Nurtec ODT/Vydura sales jumped 40% to $248 million. Prevnar family pneumococcal vaccine sales dipped 1% to $1.66 billion, and Abrysvo RSV vaccine sales slumped 6% to $131 million.
In April,&nbsp;the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44876132/us-advisory-panel-votes-to-expand-recommendation-for-pfizer-gsks-rsv-vaccines-for-older-adults-below-60-years" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>
Guidance:&nbsp;Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43463168/pfizer-q4-earnings-revenue-and-eps-beat-seagen-and-covid-19-products-show-strength-issues-strong-fy25-outlook" rel="noreferrer noopener">consensus of $62.93 billion</a>. The company anticipates adjusted EPS of $2.80-$3.00 compared to consensus of $2.96.
Pfizer <a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2025/q1/Q1-2025-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf" rel="noreferrer noopener">adds</a> the guidance does not include the potential impact of future changes in trade and tariff policies.
Cost-Cutting Initiatives: Pfizer said it plans to save an extra $1.2 billion through its ongoing cost-cutting efforts, aiming to reach that goal by the end of 2027.
The savings will mainly come from lower spending on selling, informational, and administrative expenses (SI&amp;A), thanks to more automation, use of AI, and simpler business processes.
To make these changes, Pfizer expects to spend around $1.6 billion through 2027, mostly on severance pay, tech upgrades, and implementation costs.
The company still plans to achieve $4.5 billion in savings by the end of 2025. With the new target, total program savings are expected to reach about $5.7 billion by 2027.
As part of the plan, Pfizer expects to save around $500 million by streamlining its R&amp;D operations by the end of 2026, which will be reinvested into new research. Pfizer expects to spend about $600 million to implement these R&amp;D changes.
Price Action:&nbsp;At the last check on Tuesday, PFE stock was up 3.41% to $23.84.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" target="_blank" rel="noreferrer noopener">AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty</a></li>
</ul>
Photo: ShU studio/Shutterstock

Biotech

Large Cap

Health Care

General

Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Market Perform and lowers the price target from $520 to $510.

Keefe, Bruyette & Woods Maintains Market Perform on Ameriprise Finl, Lowers Price Target to $510

WW International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares are trading higher by 110% to 87 cents during Tuesday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/04/g45066438/weightwatchers-streamlines-member-access-to-zepbound-vials-with-lillydirect-pharmacy-provider">new partnership</a> with Eli Lilly's LillyDirect pharmacy provider, Gifthealth, to simplify access to the popular weight loss drug Zepbound for its clinic members.
What To Know: WeightWatchers says this integration allows eligible self-pay patients, without insurance coverage, to receive prescriptions for Zepbound in single-dose vial form directly through the WeightWatchers app, which now includes real-time tracking and a streamlined fulfillment process.
Per WeightWatchers, Zepbound usage has surged among WeightWatchers Clinic members, with prescriptions for the vial format more than doubling in recent months. 
WeightWatchers says, currently, 33% of the clinic's patients use Zepbound as part of their weight management plan. Executives from both WeightWatchers and Gifthealth emphasized the benefits of this integration in improving transparency, pricing and ease of access. 
WeightWatchers also says the company continues to combine medical treatments like GLP-1s with behavioral support. Their approach has yielded significant results—patients have achieved an average 21% weight loss over 12 months, outperforming GLP-1 use alone.
Read Also: <a href="https://www.benzinga.com/news/25/04/45069925/coca-cola-boasts-q1-eps-beat-as-revenue-jumps-in-europe-middle-east-and-africa">Coca-Cola Boasts Q1 EPS Beat As Revenue Jumps In Europe, Middle East And Africa</a>
<h2 class="wp-block-heading">How To Buy WW Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in WW International&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WW has a 52-week high of $2.35 and a 52-week low of $0.12.

WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%

Scotiabank analyst Divya Goyal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Sector Outperform and lowers the price target from $250 to $200.

EPAM

Scotiabank Maintains Sector Outperform on EPAM Systems, Lowers Price Target to $200

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) has outperformed the market over the past 5 years by 9.06% on an annualized basis producing an average annual return of 23.33%. Currently, Johnson Controls Intl has a market capitalization of $53.59 billion. 
Buying $1000 In JCI: If an investor had bought $1000 of JCI stock 5 years ago, it would be worth $2,921.39 today based on a price of $81.18 for JCI at the time of writing.
<h3>Johnson Controls Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745940623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Johnson Controls Intl Stock In The Last 5 Years

Scotiabank analyst Divya Goyal maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Sector Perform and lowers the price target from C$2.8 to C$2.5.

TSX:ALYA

Scotiabank Maintains Sector Perform on Alithya Group, Lowers Price Target to C$2.5

WIIM

Smithfield Foods shares are trading higher following a Q1 EPS and revenue beat.

CNO Financial Group shares are trading lower after the company reported Q1 financial results.

UFPI

UFP Industries shares are trading lower after the company reported worse-than-expected Q1 financial results.

Crane shares are trading higher after the company reported better-than-expected Q1 financial results. Also, UBS upgraded the stock from Neutral to Buy and raised its price target from $157 to $190.

FELE

Franklin Electric shares are trading lower after the company reported Q1 financial results and missed its EPS and revenue estimates.

JP Morgan analyst Domingos Falavina maintains Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) with a Overweight and lowers the price target from $15 to $13.5.

VINP

JP Morgan Maintains Overweight on Vinci Partners Inv, Lowers Price Target to $13.5

LifeMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares are trading higher Tuesday after the company announced it will offer <a href="https://www.benzinga.com//node/45064487">access to Wegovy.</a>
What To Know: LifeMD said it will offer access to Wegovy through Novocare Pharmacy, allowing the company to provide the weight-loss drug at a lower self-pay price of $499 per month.
The company said this offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options.
&#8220;By embedding direct access to Wegovy&nbsp;via NovoCare Pharmacy into our platform, we&#8217;re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD&#8217;s position as a leader in delivering comprehensive, technology-enabled obesity care,&#8221; said Justin Schreiber, Chairman and CEO of LifeMD.
Related Link: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45067829/microsoft-q3-earnings-azure-may-rise-30-thats-not-where-ctos-are-aggressively-spending-analyst-warns">Microsoft Q3 Earnings: Azure May Rise 30% &#8211; That&#8217;s Not Where &#8216;CTOs Are Aggressively Spending&#8217; Analyst Warns</a>
LFMD Price Action: At the time of writing, LifeMD shares are trading 19.8% higher at $7.31, according to data from Benzinga Pro.
Image: via Shutterstock

LFMD

LifeMD Stock Pops As Company Expands Weight-Loss Offerings With Wegovy

VKTX

Viking Therapeutics shares are trading higher after Cantor FItzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $104.

Investment Summary
Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) is a leading online platform where users can shop products. The company has been successful in harnessing the power of AI that has delivered benefits to all of its stakeholders – customers, advertisers and the business internally. Moreover, transformation of its ad platform has helped the company to deliver a record quarter with over $1 billion in revenues. The company's international business, which is growing at a stellar pace compared to its US business holds promise to deliver future growth. Our fair value estimate for the stock is $36.00.
Overview
Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) is an online platform for visual search and discovery that helps its users to find inspiration, curate ideas and shop products. The company boasts of around half a billion monthly active users globally.
Several AI-based initiatives delivering significant benefits
In the last one year, PINS has undertaken several AI-based initiatives, that have delivered significant benefits. In our view, these initiatives have benefited all the stakeholders such as customers, advertisers and the business internally.
First, PINS has managed to increase the context that feeds into the AI model based on&nbsp;<a href="https://s204.q4cdn.com/369458543/files/doc_earnings/2024/q4/transcript/Q4-2024-Transcript.pdf" target="_blank" rel="noreferrer noopener">saves and clicks by 30-fold.&nbsp;</a>More powerful ML models mean better understanding of the content the customers might enjoy. We believe this has delivered significant results as evidenced by 250 bps increase in saves and 150 bps increase in outbound clicks. Moreover, this has been achieved with minimal increase in the infrastructure spend.
Second, on the monetization side, AI has helped deliver relevant ad loads to the users. In the lower funnel phase of shopping journey more ads are displayed while a few in the upper funnel of the discovery phase. This has resulted in doubling of relevance for top ad slots.
Third, is use of AI by internal engineering teams to enhance productivity. The teams use coding assistants and around 15% of the code is generated through AI.
Lastly, AI has delivered results for advertisers in terms of better performance and efficiency by automating much of the campaign process.
In our view, PINS is well positioned to harness the benefits of AI across its business processes.
Transformation of Ad Platform improves monetization and benefits advertisers
PINS has successfully managed to transform its ad platform, that in our view, not only improves monetization but also delivers several benefits to the advertisers.
In terms of lower funnel launches, PINS helped users directly access advertisers web or mobile property, thereby significantly increasing the clicks. Moreover, it used privacy centric measurement tools enabling the advertisers to accurately measure the spend.
Moreover, it launched promotional ads to highlight special offers during key promotional periods. This has resulted in 18% increase in conversion rate as compared to ads without promotion.
Further, PINS has helped advertisers to automate their campaigns and improve performance through lower CPCs and CPAs.
We believe these steps have delivered significant results. PINS has manged to report a record quarter with more than $1 billion in revenue in a single quarter underpinned by strong ad platform. Moreover, the company witnessed record revenues during cyber 5 holiday while lowering CPAs by 30% YOY.
International business &#8211; the next growth engine
With a 22% share of overall revenues for 4Q24, in our view, the international business holds promise to become the next growth engine for PINS.
The company's international business – both Europe and Rest of the World have delivered stellar performance as compared to the core US and Canada business. In terms of topline growth, Europe segment grew by 21% YOY during 4Q24 and RoW increased by a solid 44% as compared to just 16% for US and Canada.
Moreover, the MAU growth for Europe was strong at 7% and RoW reported 15% growth that is significantly better than 4% for US and Canada. Likewise, the ARPU growth for RoW was 24% that was almost double than 12% for US and Canada.
The company has entered into partnerships with Amazon Ads and Google and launched resellers in over 30 markets. In our view, these efforts are paying off as evidenced by solid topline growth for RoW throughout 2024.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="976" height="296" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1.png" alt="" class="wp-image-11821" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1.png 976w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1-300x91.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29072938/1-768x233.png 768w" sizes="(max-width: 976px) 100vw, 976px" /><figcaption class="wp-element-caption">Source: Company filings</figcaption></figure>
Share Buyback to Limit Downside
In November 2024, Pinterest announced&nbsp;<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1506293/000150629324000182/pins-20240930.htm" target="_blank" rel="noreferrer noopener">a $2 billion share repurchase program</a>. Now, I consider this significant given the fact that this represents nearly 12% of the Company's current market capitalization. In our opinion, the large share repurchase program also implies that the management is confident of generating significant free cash flow going forward. If executed well, the buyback has the potential to not only limit the price downside but enhance return for the shareholders.
Financial Projections
In our view, PINS will be able to deliver low-teens topline growth for FY25-26 driven by the strength of its international business. We expect margins to expand as Pinterest leverages its fixed costs and drive operational efficiencies. As such, we are modelling EBITDA margins to improve from 28% in FY24 to 30% in FY25. Factoring in net interest income of $108 million and tax rate of nearly 21%, leads me to diluted EPS of $1.55 for FY 2025. For 2026, we expect sales growth of 12% YOY, and an EBITDA margin of 32%. This leads to diluted EPS of $1.83 for 2026.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="465" height="308" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2.png" alt="" class="wp-image-11824" style="width:484px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2.png 465w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083535/2-300x199.png 300w" sizes="(max-width: 465px) 100vw, 465px" /></figure>
Valuation
For valuation purposes, we are using P/E relative valuation to arrive at the fair value of PINS.
We have compared PINS with some of its peers. We value PINS using target multiple of 19.4x on P/E method, in line with the peer group average. Important to note that, PINS is growing faster than many of its peers over 2024-26e and as such should command a multiple at least in line with the peer group average. Based on 2026e EPS of $1.83, the fair value estimate stands at $36.00.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="596" height="200" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3.png" alt="" class="wp-image-11825" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3.png 596w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/29083750/3-300x101.png 300w" sizes="(max-width: 596px) 100vw, 596px" /></figure>
Risks
Below are the main risks to our investment thesis:
<ul>
<li>Given that PINS generates substantially all of its revenue from advertising, any macroeconomic slowdown could hurt its growth prospects. Dependence of key categories such as consumer packaged goods and retail also remains a risk.</li>
<li>We see third-party reliance risks especially high dependence on Amazon AWS. PINS uses AWS for majority of compute, storage and data transfer. As such any disruption to the AWS services could negatively impact PINS operations.</li>
<li>High competitive intensity is a risk. The company competes with several large and well-established players such as Amazon and Google. However, we believe that PINS' focus on AI-driven personalization and ad targeting capabilities could help it mitigate rising competitive intensity.</li>
</ul>
Disclaimer
This report is based on information we consider reliable, including the subject of the report. This report does not explicitly or implicitly affirm that the information contained within this document is accurate and/or comprehensive, and as such should not be relied on in such a capacity. All information contained within this report is subject to change without any formal or other notice provided.
This document does neither constitute an offer nor a request to buy or sell any securities. It only serves informational purposes. This report does not consider individual circumstances and does not take into consideration individual investor preferences. Recipients of this report should consult professionals around their personal situation, including taxation. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in equities.
GSBR Research has not received any compensation for this article. We do not own any stock holdings nor do we have plans to purchase the shares in the next 72 hours.

Equities

Long Ideas

Retail Sales

Opinion

Media

PINS

An Under the Radar Stock With 35%+ Upside Potential

Insperity shares are trading lower after the company reported worse-than-expected Q1 financial results, cut its FY25 adjusted EPS guidance, and issued Q2 adjusted EPS guidance below estimates.

JP Morgan analyst Bill Peterson maintains Teck Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Overweight and lowers the price target from C$58 to C$57.

TSX:TECK

TSX:TECK/B

JP Morgan Maintains Overweight on Teck Resources, Lowers Price Target to C$57

Press Releases

FOXO TECHNOLOGIES INC. ANOUNCES DETAILS OF ITS 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 31, 2024

FOXO TECHNOLOGIES INC.'S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS

FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON JANUARY 17, 2025.

FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

FOXO TECHNOLOGIES, INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR TWO ASSISTED-LIVING FACILITIES IN FLORIDA FOR A TOTAL CONSIDERATION OF $60 MILLION

Comments

FOXO Technologies

FOXO Technologies (FOXO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル